Neoatherosclerosis: Another Consequence of Endothelial Dysfunction?

Leopold, Jane A.

doi:10.1161/circinterventions.114.001994

Cited by 12 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 A previous report speculated that neoatherosclerosis is 1 consequence of endothelial dysfunction. 12 Endothelial function was better preserved in a newer generation DES compared with a first-generation DES, and re-endothelialization is associated with preserved endothelial function. 13 It is possible that SES implantation in VSA patients impacts on late progression, and that N-DES implantation in VSA patients is not related to progression or regression of lateterm in-stent stenosis.…”

Section: Clinical Follow-up Outcomesmentioning

confidence: 92%

Impact of Stent Type and Presence of Vasospastic Angina on Long-Term Prognosis

Hata

Oka

Kubo

et al. 2018

Circ J

View full text Add to dashboard Cite

Section: Clinical Follow-up Outcomesmentioning

confidence: 92%

Impact of Stent Type and Presence of Vasospastic Angina on Long-Term Prognosis

Hata

Oka

Kubo

et al. 2018

Circ J

View full text Add to dashboard Cite

“…A new endothelium starts to be formed immediately after stenting (in vivo studies showed a neoendothelium after one week of implantation [59]), but regenerated cells have to be healthy. A functional endothelium is key to preventing neoatherosclerosis and previous studies on drug-eluting stents revealed a functionally incompetent regenerated endothelium [64]. Additionally, optimal blood compatibility can only be achieved by a monolayer of normal endothelial cells [65].…”

Section: In Vivo Testsmentioning

confidence: 99%

Are Fe-Based Stenting Materials Biocompatible? A Critical Review of In Vitro and In Vivo Studies

Scarcello

Lison

2019

JFB

View full text Add to dashboard Cite

Fe-based materials have increasingly been considered for the development of biodegradable cardiovascular stents. A wide range of in vitro and in vivo studies should be done to fully evaluate their biocompatibility. In this review, we summarized and analyzed the findings and the methodologies used to assess the biocompatibility of Fe materials. The majority of investigators drew conclusions about in vitro Fe toxicity based on indirect contact results. The setup applied in these tests seems to overlook the possible effects of Fe corrosion and does not allow for understanding of the complexity of released chemical forms and their possible impact on tissue. It is in particular important to ensure that test setups or interpretations of in vitro results do not hide some important mechanisms, leading to inappropriate subsequent in vivo experiments. On the other hand, the sample size of existing in vivo implantations is often limited, and effects such as local toxicity or endothelial function are not deeply scrutinized. The main advantages and limitations of in vitro design strategies applied in the development of Fe-based alloys and the correlation with in vivo studies are discussed. It is evident from this literature review that we are not yet ready to define an Fe-based material as safe or biocompatible.

show abstract

“…A few studies conducted to date have identified that endothelial dysfunction and consequent neoatherosclerosis play a role in the development of late adverse events [3]. …”

Section: Introductionmentioning

confidence: 99%

Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents

Yin

Shen

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Late in-stent restenosis (ISR) has raised concerns regarding the long-term efficacy of drug-eluting stents (DES). The role of vascular endothelial growth factor (VEGF) in the pathological process of ISR is controversial. This retrospective study aimed to investigate the relationship between serum VEGF levels and late ISR in patients with DES implantation. A total of 158 patients who underwent angiography follow-up beyond 1 year after intervention were included. The study population was classified into ISR and non-ISR groups. The ISR group was further divided according to follow-up duration and Mehran classification. VEGF levels were significantly lower in the ISR group than in the non-ISR group [96.34 (48.18, 174.14) versus 179.14 (93.59, 307.74) pg/mL, p < 0.0001]. Multivariate regression revealed that VEGF level, procedure age, and low-density lipoprotein cholesterol were independent risk factors for late ISR formation. Subgroup analysis demonstrated that VEGF levels were even lower in the very late (≥5 years) and diffuse ISR group (Mehran patterns II, III, and IV) than in the late ISR group (1–4 years) and the focal ISR group (Mehran pattern I), respectively. Furthermore, significant difference was found between diffuse and focal ISR groups. Serum VEGF levels were inversely associated with late ISR after DES implantation.

show abstract

Neoatherosclerosis: Another Consequence of Endothelial Dysfunction?

Cited by 12 publications

References 22 publications

Impact of Stent Type and Presence of Vasospastic Angina on Long-Term Prognosis

Impact of Stent Type and Presence of Vasospastic Angina on Long-Term Prognosis

Are Fe-Based Stenting Materials Biocompatible? A Critical Review of In Vitro and In Vivo Studies

Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents

Contact Info

Product

Resources

About